TY - JOUR AU - Czech, M. P. PY - 2000 DA - 2000// TI - PIP2 and PIP3: complex roles at the cell surface JO - Cell VL - 100 UR - https://doi.org/10.1016/S0092-8674(00)80696-0 DO - 10.1016/S0092-8674(00)80696-0 ID - Czech2000 ER - TY - JOUR AU - Cantrell, D. A. PY - 2001 DA - 2001// TI - Phosphoinositide 3-kinase signalling pathways JO - J Cell Sci VL - 114 ID - Cantrell2001 ER - TY - JOUR AU - Hu, C. AU - Huang, L. AU - Gest, C. AU - Xi, X. AU - Janin, A. AU - Soria, C. AU - Li, H. AU - Lu, H. PY - 2012 DA - 2012// TI - Opposite regulation by PI3K/Akt and MAPK/ERK pathways of tissue factor expression, cell-associated procoagulant activity and invasiveness in MDA-MB-231 cells JO - J Hematol Oncol VL - 5 UR - https://doi.org/10.1186/1756-8722-5-16 DO - 10.1186/1756-8722-5-16 ID - Hu2012 ER - TY - JOUR AU - Shenker, B. J. AU - Ali, H. AU - Boesze-Battaglia, K. PY - 2011 DA - 2011// TI - PIP3 regulation as promising targeted therapy of mast-cell-mediated diseases JO - Curr Pharm Des VL - 17 UR - https://doi.org/10.2174/138161211798357926 DO - 10.2174/138161211798357926 ID - Shenker2011 ER - TY - JOUR AU - Akinleye, A. AU - Avvaru, P. AU - Furqan, M. AU - Song, Y. AU - Liu, D. PY - 2013 DA - 2013// TI - Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics JO - J Hematol Oncol VL - 6 UR - https://doi.org/10.1186/1756-8722-6-88 DO - 10.1186/1756-8722-6-88 ID - Akinleye2013 ER - TY - JOUR AU - Vivanco, I. AU - Sawyers, C. L. PY - 2002 DA - 2002// TI - The phosphatidylinositol 3-Kinase AKT pathway in human cancer JO - Nat Rev Cancer VL - 2 UR - https://doi.org/10.1038/nrc839 DO - 10.1038/nrc839 ID - Vivanco2002 ER - TY - JOUR AU - Dubrovska, A. AU - Kim, S. AU - Salamone, R. J. AU - Walker, J. R. AU - Maira, S. M. AU - Garcia-Echeverria, C. AU - Schultz, P. G. AU - Reddy, V. A. PY - 2009 DA - 2009// TI - The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations JO - Proc Natl Acad Sci USA VL - 106 UR - https://doi.org/10.1073/pnas.0810956106 DO - 10.1073/pnas.0810956106 ID - Dubrovska2009 ER - TY - JOUR AU - Polak, R. AU - Buitenhuis, M. PY - 2012 DA - 2012// TI - The PI3K/PKB signaling module as key regulator of hematopoiesis: implications for therapeutic strategies in leukemia JO - Blood VL - 119 UR - https://doi.org/10.1182/blood-2011-07-366203 DO - 10.1182/blood-2011-07-366203 ID - Polak2012 ER - TY - JOUR AU - Fang, X. AU - Zhou, X. AU - Wang, X. PY - 2013 DA - 2013// TI - Clinical development of phosphatidylinositol 3-kinase inhibitors for non-Hodgkin lymphoma JO - Biomark Res VL - 1 UR - https://doi.org/10.1186/2050-7771-1-30 DO - 10.1186/2050-7771-1-30 ID - Fang2013 ER - TY - JOUR AU - Li, J. AU - Zhu, J. AU - Cao, B. AU - Mao, X. PY - 2014 DA - 2014// TI - The mTOR signaling pathway is an emerging therapeutic target in multiple myeloma JO - Curr Pharm Des VL - 20 UR - https://doi.org/10.2174/13816128113199990638 DO - 10.2174/13816128113199990638 ID - Li2014 ER - TY - JOUR AU - Mao, X. AU - Cao, B. AU - Wood, T. E. AU - Hurren, R. AU - Tong, J. AU - Wang, X. AU - Wang, W. AU - Li, J. AU - Jin, Y. AU - Sun, W. PY - 2011 DA - 2011// TI - A small-molecule inhibitor of D-cyclin transactivation displays preclinical efficacy in myeloma and leukemia via phosphoinositide 3-kinase pathway JO - Blood VL - 117 UR - https://doi.org/10.1182/blood-2010-05-284810 DO - 10.1182/blood-2010-05-284810 ID - Mao2011 ER - TY - JOUR AU - Falasca, M. PY - 2010 DA - 2010// TI - PI3K/Akt signalling pathway specific inhibitors: a novel strategy to sensitize cancer cells to anti-cancer drugs JO - Curr Pharm Des VL - 16 UR - https://doi.org/10.2174/138161210791033950 DO - 10.2174/138161210791033950 ID - Falasca2010 ER - TY - JOUR AU - Courtney, K. D. AU - Corcoran, R. B. AU - Engelman, J. A. PY - 2010 DA - 2010// TI - The PI3K pathway as drug target in human cancer JO - J Clin Oncol VL - 28 UR - https://doi.org/10.1200/JCO.2009.25.3641 DO - 10.1200/JCO.2009.25.3641 ID - Courtney2010 ER - TY - JOUR AU - Wu, P. AU - Hu, Y. Z. PY - 2010 DA - 2010// TI - PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress JO - Curr Med Chem VL - 17 UR - https://doi.org/10.2174/092986710793361234 DO - 10.2174/092986710793361234 ID - Wu2010 ER - TY - JOUR AU - Hennessy, B. T. AU - Smith, D. L. AU - Ram, P. T. AU - Lu, Y. AU - Mills, G. B. PY - 2005 DA - 2005// TI - Exploiting the PI3K/AKT pathway for cancer drug discovery JO - Nat Rev Drug Discov VL - 4 UR - https://doi.org/10.1038/nrd1902 DO - 10.1038/nrd1902 ID - Hennessy2005 ER - TY - JOUR AU - Bianchi, G. AU - Kumar, S. AU - Ghobrial, I. M. AU - Roccaro, A. M. PY - 2012 DA - 2012// TI - Cell trafficking in multiple myeloma JO - Open J Hematol VL - 3 UR - https://doi.org/10.13055/ojhmt_3_S1_04.120221 DO - 10.13055/ojhmt_3_S1_04.120221 ID - Bianchi2012 ER - TY - JOUR AU - Sutherlin, D. P. AU - Baker, S. AU - Bisconte, A. AU - Blaney, P. M. AU - Brown, A. AU - Chan, B. K. AU - Chantry, D. AU - Castanedo, G. AU - DePledge, P. AU - Goldsmith, P. PY - 2012 DA - 2012// TI - Potent and selective inhibitors of PI3Kdelta: obtaining isoform selectivity from the affinity pocket and tryptophan shelf JO - Bioorg Med Chem Lett VL - 22 UR - https://doi.org/10.1016/j.bmcl.2012.05.027 DO - 10.1016/j.bmcl.2012.05.027 ID - Sutherlin2012 ER - TY - JOUR AU - Zhang, J. AU - Choi, Y. AU - Mavromatis, B. AU - Lichtenstein, A. AU - Li, W. PY - 2003 DA - 2003// TI - Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway JO - Oncogene VL - 22 UR - https://doi.org/10.1038/sj.onc.1206718 DO - 10.1038/sj.onc.1206718 ID - Zhang2003 ER - TY - JOUR AU - Ramakrishnan, V. AU - Kimlinger, T. AU - Haug, J. AU - Painuly, U. AU - Wellik, L. AU - Halling, T. AU - Rajkumar, S. V. AU - Kumar, S. PY - 2012 DA - 2012// TI - Anti-myeloma activity of Akt inhibition is linked to the activation status of PI3K/Akt and MEK/ERK pathway JO - PLoS One VL - 7 UR - https://doi.org/10.1371/journal.pone.0050005 DO - 10.1371/journal.pone.0050005 ID - Ramakrishnan2012 ER - TY - JOUR AU - Hsu, J. AU - Shi, Y. AU - Krajewski, S. AU - Renner, S. AU - Fisher, M. AU - Reed, J. C. AU - Franke, T. F. AU - Lichtenstein, A. PY - 2001 DA - 2001// TI - The AKT kinase is activated in multiple myeloma tumor cells JO - Blood VL - 98 UR - https://doi.org/10.1182/blood.V98.9.2853 DO - 10.1182/blood.V98.9.2853 ID - Hsu2001 ER - TY - JOUR AU - Meadows, S. A. AU - Vega, F. AU - Kashishian, A. AU - Johnson, D. AU - Diehl, V. AU - Miller, L. L. AU - Younes, A. AU - Lannutti, B. J. PY - 2011 DA - 2011// TI - PI3Kdelta inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma JO - Blood VL - 119 UR - https://doi.org/10.1182/blood-2011-10-386763 DO - 10.1182/blood-2011-10-386763 ID - Meadows2011 ER - TY - JOUR AU - Brachmann, S. M. AU - Kleylein-Sohn, J. AU - Gaulis, S. AU - Kauffmann, A. AU - Blommers, M. J. AU - Kazic-Legueux, M. AU - Laborde, L. AU - Hattenberger, M. AU - Stauffer, F. AU - Vaxelaire, J. PY - 2012 DA - 2012// TI - Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations JO - Mol Cancer Ther VL - 11 UR - https://doi.org/10.1158/1535-7163.MCT-11-1021 DO - 10.1158/1535-7163.MCT-11-1021 ID - Brachmann2012 ER - TY - JOUR AU - Richardson, P. G. AU - Eng, C. AU - Kolesar, J. AU - Hideshima, T. AU - Anderson, K. C. PY - 2012 DA - 2012// TI - Perifosine, an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity JO - Expert Opin Drug Metab Toxicol VL - 8 UR - https://doi.org/10.1517/17425255.2012.681376 DO - 10.1517/17425255.2012.681376 ID - Richardson2012 ER - TY - JOUR AU - Ma, J. AU - Sawai, H. AU - Matsuo, Y. AU - Ochi, N. AU - Yasuda, A. AU - Takahashi, H. AU - Wakasugi, T. AU - Funahashi, H. AU - Sato, M. AU - Takeyama, H. PY - 2010 DA - 2010// TI - IGF-1 mediates PTEN suppression and enhances cell invasion and proliferation via activation of the IGF-1/PI3K/Akt signaling pathway in pancreatic cancer cells JO - J Surg Res VL - 160 UR - https://doi.org/10.1016/j.jss.2008.08.016 DO - 10.1016/j.jss.2008.08.016 ID - Ma2010 ER - TY - JOUR AU - Park, S. AU - Chapuis, N. AU - Tamburini, J. AU - Bardet, V. AU - Cornillet-Lefebvre, P. AU - Willems, L. AU - Green, A. AU - Mayeux, P. AU - Lacombe, C. AU - Bouscary, D. PY - 2010 DA - 2010// TI - Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia JO - Haematologica VL - 95 UR - https://doi.org/10.3324/haematol.2009.013797 DO - 10.3324/haematol.2009.013797 ID - Park2010 ER - TY - JOUR AU - Bhatt, A. P. AU - Bhende, P. M. AU - Sin, S. H. AU - Roy, D. AU - Dittmer, D. P. AU - Damania, B. PY - 2010 DA - 2010// TI - Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas JO - Blood VL - 115 UR - https://doi.org/10.1182/blood-2009-10-251082 DO - 10.1182/blood-2009-10-251082 ID - Bhatt2010 ER - TY - JOUR AU - Rodon, J. AU - Dienstmann, R. AU - Serra, V. AU - Tabernero, J. PY - 2013 DA - 2013// TI - Development of PI3K inhibitors: lessons learned from early clinical trials JO - Nat Rev Clin Oncol VL - 10 UR - https://doi.org/10.1038/nrclinonc.2013.10 DO - 10.1038/nrclinonc.2013.10 ID - Rodon2013 ER - TY - JOUR AU - Guo, Y. Q. AU - Chen, S. L. PY - 2006 DA - 2006// TI - [The significance of IGF-1, VEGF, IL-6 in multiple myeloma progression] JO - Zhonghua Xue Ye Xue Za Zhi VL - 27 ID - Guo2006 ER - TY - JOUR AU - Shannon, E. J. AU - Morales, M. J. AU - Sandoval, F. PY - 1997 DA - 1997// TI - Immunomodulatory assays to study structure-activity relationships of thalidomide JO - Immunopharmacology VL - 35 UR - https://doi.org/10.1016/S0162-3109(96)00149-X DO - 10.1016/S0162-3109(96)00149-X ID - Shannon1997 ER - TY - JOUR AU - Hideshima, T. AU - Chauhan, D. AU - Shima, Y. AU - Raje, N. AU - Davies, F. E. AU - Tai, Y. T. AU - Treon, S. P. AU - Lin, B. AU - Schlossman, R. L. AU - Richardson, P. PY - 2000 DA - 2000// TI - Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy JO - Blood VL - 96 ID - Hideshima2000 ER - TY - JOUR AU - Shimazawa, R. AU - Sano, H. AU - Tanatani, A. AU - Miyachi, H. AU - Hashimoto, Y. PY - 2004 DA - 2004// TI - Thalidomide as a nitric oxide synthase inhibitor and its structural development JO - Chem Pharm Bull (Tokyo) VL - 52 UR - https://doi.org/10.1248/cpb.52.498 DO - 10.1248/cpb.52.498 ID - Shimazawa2004 ER - TY - JOUR AU - Hashimoto, Y. PY - 2002 DA - 2002// TI - Structural development of biological response modifiers based on thalidomide JO - Bioorg Med Chem VL - 10 UR - https://doi.org/10.1016/S0968-0896(01)00308-X DO - 10.1016/S0968-0896(01)00308-X ID - Hashimoto2002 ER - TY - JOUR AU - Richardson, P. AU - Anderson, K. PY - 2004 DA - 2004// TI - Immunomodulatory analogs of thalidomide: an emerging new therapy in myeloma JO - J Clin Oncol VL - 22 UR - https://doi.org/10.1200/JCO.2004.05.984 DO - 10.1200/JCO.2004.05.984 ID - Richardson2004 ER - TY - JOUR AU - Foukas, L. C. AU - Berenjeno, I. M. AU - Gray, A. AU - Khwaja, A. AU - Vanhaesebroeck, B. PY - 2010 DA - 2010// TI - Activity of any class IA PI3K isoform can sustain cell proliferation and survival JO - Proc Natl Acad Sci USA VL - 107 UR - https://doi.org/10.1073/pnas.0906461107 DO - 10.1073/pnas.0906461107 ID - Foukas2010 ER - TY - JOUR AU - Ghigo, A. AU - Damilano, F. AU - Braccini, L. AU - Hirsch, E. PY - 2010 DA - 2010// TI - PI3K inhibition in inflammation: Toward tailored therapies for specific diseases JO - Bioessays VL - 32 UR - https://doi.org/10.1002/bies.200900150 DO - 10.1002/bies.200900150 ID - Ghigo2010 ER - TY - JOUR AU - Hart, J. R. AU - Vogt, P. K. PY - 2011 DA - 2011// TI - Phosphorylation of AKT: a mutational analysis JO - Oncotarget VL - 2 UR - https://doi.org/10.18632/oncotarget.293 DO - 10.18632/oncotarget.293 ID - Hart2011 ER - TY - JOUR AU - Markman, B. AU - Dienstmann, R. AU - Tabernero, J. PY - 2010 DA - 2010// TI - Targeting the PI3K/Akt/mTOR pathway--beyond rapalogs JO - Oncotarget VL - 1 UR - https://doi.org/10.18632/oncotarget.188 DO - 10.18632/oncotarget.188 ID - Markman2010 ER - TY - JOUR AU - Chung, J. AU - Kuo, C. J. AU - Crabtree, G. R. AU - Blenis, J. PY - 1992 DA - 1992// TI - Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases JO - Cell VL - 69 UR - https://doi.org/10.1016/0092-8674(92)90643-Q DO - 10.1016/0092-8674(92)90643-Q ID - Chung1992 ER - TY - JOUR AU - Gingras, A. C. AU - Kennedy, S. G. AU - O’Leary, M. A. AU - Sonenberg, N. AU - Hay, N. PY - 1998 DA - 1998// TI - 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway JO - Genes Dev VL - 12 UR - https://doi.org/10.1101/gad.12.4.502 DO - 10.1101/gad.12.4.502 ID - Gingras1998 ER - TY - JOUR AU - She, Q. B. AU - Halilovic, E. AU - Ye, Q. AU - Zhen, W. AU - Shirasawa, S. AU - Sasazuki, T. AU - Solit, D. B. AU - Rosen, N. PY - 2010 DA - 2010// TI - 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors JO - Cancer Cell VL - 18 UR - https://doi.org/10.1016/j.ccr.2010.05.023 DO - 10.1016/j.ccr.2010.05.023 ID - She2010 ER - TY - JOUR AU - Yin, S. Q. AU - Shi, M. AU - Kong, T. T. AU - Zhang, C. M. AU - Han, K. AU - Cao, B. AU - Zhang, Z. AU - Du, X. AU - Tang, L. Q. AU - Mao, X. PY - 2013 DA - 2013// TI - Preparation of S14161 and its analogues and the discovery of 6-bromo-8-ethoxy-3-nitro-2H-chromene as a more potent antitumor agent in vitro JO - Bioorg Med Chem Lett VL - 23 UR - https://doi.org/10.1016/j.bmcl.2013.03.097 DO - 10.1016/j.bmcl.2013.03.097 ID - Yin2013 ER - TY - JOUR AU - Ling, C. AU - Chen, G. AU - Chen, G. AU - Zhang, Z. AU - Cao, B. AU - Han, K. AU - Yin, J. AU - Chu, A. AU - Zhao, Y. AU - Mao, X. PY - 2012 DA - 2012// TI - A deuterated analog of dasatinib disrupts cell cycle progression and displays anti-non-small cell lung cancer activity in vitro and in vivo JO - Int J Cancer VL - 131 UR - https://doi.org/10.1002/ijc.27504 DO - 10.1002/ijc.27504 ID - Ling2012 ER -